AGEN-2385
- Generic Name
- AGEN-2385
Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma
- Conditions
- Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8Clinical Stage IV Merkel Cell Carcinoma AJCC v8Merkel Cell Carcinoma
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 12
- Registration Number
- NCT06056895
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Head and Neck Cancer
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Incyte Biosciences International SÃ rl
- Target Recruit Count
- 176
- Registration Number
- NCT05287113
- Locations
- 🇬🇷
Saint Lukas Clinic, Thessaloniki, Greece
🇵🇱Przychodnia Lekarska Komed Roman Karaszewski, Konin, Poland
🇵🇱Nzoz Provita Prolife Centrum Medyczne, Tomaszow Mazowiecki, Poland
An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04586244
- Locations
- 🇮🇹
Istituto Tumori Giovanni Paolo Ii Irccs Ospedale Oncologico Bari, Bari, Italy
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇫🇷Institut Gustave Roussy, Villejuif Cedex, France
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
- Conditions
- Endometrial Cancer
- Interventions
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 300
- Registration Number
- NCT04463771
- Locations
- 🇺🇸
Advent Health Medical Group-Orlando 2501, Orlando, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida, United States
🇺🇸Alaska Womens Cancer Care Akwcc, Anchorage, Alaska, United States
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2020-05-01
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 61
- Registration Number
- NCT04370704
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.